Evidence map›Paper›PMID 39655912›Full record

ArticleAntimicrobial agents and chemotherapy2025

Yasmeen Abouelhassan, Yuwei Shen, April Chen, Xiaoyi Ye, David P Nicolau, Joseph L Kuti

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Antimicrobial agents and chemotherapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yasmeen AbouelhassanCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Yuwei ShenCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
April ChenInnoviva Specialty Therapeutics Inc, Waltham, Massachusetts, USA.
Xiaoyi YeDivision of Nephrology, Hartford Hospital, Hartford, Connecticut, USA.
David P NicolauCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4148-0165
Joseph L KutiCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4464-3126

Funding

Innoviva Specialty Therapeutics
6 · The paper itself

Abstract

Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsContinuous Renal Replacement TherapySulbactamAcinetobacter baumanniiAcinetobacter InfectionsHemofiltrationHumansMonte Carlo MethodPneumonia, Ventilator-AssociatedRenal DialysisAnti-Bacterial AgentsAzabicyclo CompoundsdurlobactamSulbactamAcinetobacter baumanniiCVVHdosingMonte Carlo simulationpharmacodynamicsrenal replacementsulbactam-durlobactam

Identifiers

PMID39655912
PMCPMC11784458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.